Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

09/08/2011 | 10:10pm US/Eastern

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

React to this article
Latest news on ASTELLAS PHARMA INC
07/24 ASTELLAS PHARMA : Initiates Collaborative Research with National Institute of Ad..
07/23 ASTELLAS PHARMA : Initiates Collaborative Research with National Institute of Ad..
07/23 ASTELLAS PHARMA : "Cell therapy using human iPSC-derived renal progenitors ameli..
07/22 ASTELLAS PHARMA : Researchers from Astellas Pharma, Inc. Detail Findings in Phar..
07/22 ASTELLAS PHARMA : - 'Cell therapy using human iPSC-derived renal progenitors ame..
07/21 ASTELLAS PHARMA : "Cell therapy using human iPSC-derived renal progenitors ameli..
07/20 SEATTLE GENETICS : Agensys Assigned Patent
07/16 ASTELLAS PHARMA : The Netherlands Decorates Masafumi Nogimori, Representative Di..
07/16 ASTELLAS PHARMA : The Netherlands Decorates Masafumi Nogimori, Representative Di..
07/15DJASIAN SHARES : China Stocks Tumble as Investors Doubt Beijing's Help
Advertisement
Chart
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Income Statement Evolution
More Financials